Sutro Biopharma, Inc. - Common Stock, $0.001 par value (STRO)
CUSIP: 869367102
Q1 2025 13F Holders as of 31 Mar 2025
- Type / Class
- Equity / Common Stock, $0.001 par value
- Shares outstanding
- 84,733,230
- Total 13F shares
- 61,457,334
- Share change
- -1,410,222
- Total reported value
- $39,985,859
- Put/Call ratio
- 185%
- Price per share
- $0.65
- Number of holders
- 113
- Value change
- -$10,841,219
- Number of buys
- 55
- Number of sells
- 59
Quarterly Holders Quick Answers
What is CUSIP 869367102?
CUSIP 869367102 identifies STRO - Sutro Biopharma, Inc. - Common Stock, $0.001 par value in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 869367102:
Top shareholders of STRO - Sutro Biopharma, Inc. - Common Stock, $0.001 par value (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| BlackRock, Inc. |
13F
|
Company |
9%
|
7,593,191
|
$13,971,471 | — | 31 Dec 2024 | |
| SUVRETTA CAPITAL MANAGEMENT, LLC |
13F
|
Company |
8.8%
|
7,462,495
|
$13,730,991 | — | 31 Dec 2024 | |
| VANGUARD GROUP INC |
13F
|
Company |
5%
|
4,208,500
|
$7,743,639 | — | 31 Dec 2024 | |
| Kynam Capital Management, LP |
13F
13D/G
|
Company |
6.4%
from 13D/G
|
3,641,447
|
$6,700,262 | — | 31 Dec 2024 | |
| Merck & Co., Inc. |
13F
|
Company |
3.2%
|
2,723,509
|
$5,011,257 | — | 31 Dec 2024 | |
| Vestal Point Capital, LP |
13F
|
Company |
3%
|
2,570,000
|
$4,728,800 | — | 31 Dec 2024 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
2.9%
|
2,458,657
|
$4,523,929 | — | 31 Dec 2024 | |
| Point72 Asset Management, L.P. |
13F
|
Company |
2.6%
|
2,197,538
|
$4,043,470 | — | 31 Dec 2024 | |
| Samsara BioCapital, LLC |
13F
|
Company |
2.6%
|
2,196,814
|
$4,042,138 | — | 31 Dec 2024 | |
| MPM BioImpact LLC |
13F
|
Company |
2.5%
|
2,160,062
|
$3,974,514 | — | 31 Dec 2024 | |
| ADAGE CAPITAL PARTNERS GP, L.L.C. |
13F
|
Company |
2.4%
|
2,000,000
|
$3,680,000 | — | 31 Dec 2024 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
2.2%
|
1,854,017
|
$3,412,047 | — | 31 Dec 2024 | |
| ACADIAN ASSET MANAGEMENT LLC |
13F
|
Company |
2.1%
|
1,751,925
|
$3,221,000 | — | 31 Dec 2024 | |
| Parkman Healthcare Partners LLC |
13F
|
Company |
2%
|
1,727,925
|
$3,179,382 | — | 31 Dec 2024 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
2%
|
1,714,422
|
$3,154,537 | — | 31 Dec 2024 | |
| STATE STREET CORP |
13F
|
Company |
2%
|
1,701,870
|
$3,131,441 | — | 31 Dec 2024 | |
| MORGAN STANLEY |
13F
|
Company |
1.8%
|
1,520,136
|
$2,797,052 | — | 31 Dec 2024 | |
| Nuveen Asset Management, LLC |
13F
|
Company |
1.6%
|
1,323,777
|
$2,435,749 | — | 31 Dec 2024 | |
| DIMENSIONAL FUND ADVISORS LP |
13F
|
Company |
1.3%
|
1,136,457
|
$2,091,162 | — | 31 Dec 2024 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
1.2%
|
1,015,211
|
$1,867,988 | — | 31 Dec 2024 | |
| JACOBS LEVY EQUITY MANAGEMENT, INC |
13F
|
Company |
1%
|
859,373
|
$1,581,246 | — | 31 Dec 2024 | |
| William J. Newell |
3/4/5
|
CEO, Director |
—
mixed-class rows
|
768,806
mixed-class rows
|
$1,399,621 | — | 05 Mar 2025 | |
| Eversept Partners, LP |
13F
|
Company |
0.82%
|
694,408
|
$1,277,711 | — | 31 Dec 2024 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.75%
|
636,920
|
$1,171,932 | — | 31 Dec 2024 | |
| TWO SIGMA ADVISERS, LP |
13F
|
Company |
0.65%
|
547,800
|
$1,007,952 | — | 31 Dec 2024 | |
| PRUDENTIAL FINANCIAL INC |
13F
|
Company |
0.65%
|
547,510
|
$1,007,418 | — | 31 Dec 2024 | |
| DAFNA Capital Management LLC |
13F
|
Company |
0.52%
|
437,079
|
$804,225 | — | 31 Dec 2024 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
0.48%
|
405,618
|
$746,337 | — | 31 Dec 2024 | |
| LPL Financial LLC |
13F
|
Company |
0.43%
|
362,232
|
$666,507 | — | 31 Dec 2024 | |
| Connor, Clark & Lunn Investment Management Ltd. |
13F
|
Company |
0.39%
|
326,317
|
$600,423 | — | 31 Dec 2024 | |
| TWO SIGMA INVESTMENTS, LP |
13F
|
Company |
0.37%
|
316,292
|
$581,977 | — | 31 Dec 2024 | |
| OCONNOR, A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS (LLC) |
13F
|
Company |
0.35%
|
300,621
|
$553,143 | — | 31 Dec 2024 | |
| FMR LLC |
13F
|
Company |
0.33%
|
277,892
|
$511,321 | — | 31 Dec 2024 | |
| Trevor Hallam |
3/4/5
|
Pres. Rsrch & Cf. Sctific Ofcr |
—
mixed-class rows
|
107,868
mixed-class rows
|
$507,563 | — | 14 Apr 2023 | |
| Fisher Asset Management, LLC |
13F
|
Company |
0.32%
|
271,337
|
$499,260 | — | 31 Dec 2024 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.3%
|
251,995
|
$463,671 | — | 31 Dec 2024 | |
| Bank of New York Mellon Corp |
13F
|
Company |
0.26%
|
217,627
|
$400,433 | — | 31 Dec 2024 | |
| Shay Capital LLC |
13F
|
Company |
0.24%
|
203,601
|
$374,626 | — | 31 Dec 2024 | |
| Schonfeld Strategic Advisors LLC |
13F
|
Company |
0.23%
|
196,800
|
$362,112 | — | 31 Dec 2024 | |
| Arturo Molina MD |
3/4/5
|
Chief Medical Officer |
—
mixed-class rows
|
127,236
mixed-class rows
|
$354,016 | — | 04 Mar 2022 | |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.22%
|
189,700
|
$349,048 | — | 31 Dec 2024 | |
| UBS Group AG |
13F
|
Company |
0.22%
|
183,661
|
$337,936 | — | 31 Dec 2024 | |
| AMERIPRISE FINANCIAL INC |
13F
|
Company |
0.21%
|
180,401
|
$331,938 | — | 31 Dec 2024 | |
| AJU IB Investment Co., Ltd. |
13F
|
Company |
0.21%
|
175,000
|
$322,000 | — | 31 Dec 2024 | |
| BARCLAYS PLC |
13F
|
Company |
0.19%
|
158,814
|
$292,218 | — | 31 Dec 2024 | |
| D. E. Shaw & Co., Inc. |
13F
|
Company |
0.19%
|
157,683
|
$290,137 | — | 31 Dec 2024 | |
| STRS OHIO |
13F
|
Company |
0.18%
|
152,800
|
$281,152 | — | 31 Dec 2024 | |
| BNP PARIBAS FINANCIAL MARKETS |
13F
|
Company |
0.18%
|
150,758
|
$277,395 | — | 31 Dec 2024 | |
| Shabbir Anik |
3/4/5
|
Chief Technical Ops. Officer |
—
mixed-class rows
|
58,327
mixed-class rows
|
$274,452 | — | 03 Mar 2023 | |
| PANAGORA ASSET MANAGEMENT INC |
13F
|
Company |
0.17%
|
142,186
|
$261,622 | — | 31 Dec 2024 |
Institutional Holders of Sutro Biopharma, Inc. - Common Stock, $0.001 par value (STRO) as of Q1 2025
As of 31 Mar 2025,
Sutro Biopharma, Inc. - Common Stock, $0.001 par value (STRO) was held by
113 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
61,457,334 shares.
The largest 10 holders included
SUVRETTA CAPITAL MANAGEMENT, LLC, BlackRock, Inc., Kynam Capital Management, LP, RA CAPITAL MANAGEMENT, L.P., VANGUARD GROUP INC, ACADIAN ASSET MANAGEMENT LLC, Merck & Co., Inc., Vestal Point Capital, LP, Eversept Partners, LP, and SAMSARA BIOCAPITAL, LLC.
This page lists
113
institutional shareholders reporting positions in this security
for the Q1 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q1 2025 vs Q4 2024 Across Filers
Q4 2024 holders
122
Q1 2025 holders
113
Holder diff
-9
| Investor | Q4 2024 Shares | Q1 2025 Shares | Share Diff | Share Chg % | Q4 2024 Value $ | Q1 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.